Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023
17 nov. 2023 01h00 HE
|
Xeltis
Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date...
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing
14 août 2023 02h00 HE
|
Xeltis
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing Funding extends Xeltis’ Series D2 financing round to €44.5 million EINDHOVEN, The...
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress
28 avr. 2023 02h00 HE
|
Xeltis
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of...
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices
21 févr. 2023 01h00 HE
|
Xeltis
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...